Emergent Biosolutions (NYSE:EBS) had its target price lifted by stock analysts at Chardan Capital from $47.00 to $53.00 in a report released on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Chardan Capital’s price target would suggest a potential upside of 11.49% from the stock’s current price.

A number of other equities analysts also recently issued reports on the company. Zacks Investment Research downgraded Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Wells Fargo & Co reissued an “outperform” rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th.

Emergent Biosolutions (NYSE EBS) opened at $47.54 on Tuesday. The stock has a market capitalization of $1,967.94, a P/E ratio of 28.13, a price-to-earnings-growth ratio of 0.99 and a beta of 1.25. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38. Emergent Biosolutions has a 1 year low of $27.94 and a 1 year high of $49.25.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.32. The company had revenue of $149.43 million for the quarter, compared to the consensus estimate of $124.55 million. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. Emergent Biosolutions’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.56 earnings per share. equities analysts forecast that Emergent Biosolutions will post 1.66 EPS for the current fiscal year.

In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 21,906 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $47.91, for a total transaction of $1,049,516.46. Following the completion of the transaction, the chief executive officer now owns 226,040 shares of the company’s stock, valued at $10,829,576.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Fuad El-Hibri sold 40,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $40.37, for a total value of $1,614,800.00. The disclosure for this sale can be found here. Insiders have sold 206,329 shares of company stock valued at $8,892,362 in the last three months. Insiders own 16.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in the business. Northern Trust Corp increased its holdings in shares of Emergent Biosolutions by 47.2% in the second quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock valued at $30,747,000 after purchasing an additional 290,863 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Emergent Biosolutions by 7.4% in the second quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock valued at $74,795,000 after purchasing an additional 152,029 shares during the last quarter. Peregrine Capital Management LLC increased its holdings in shares of Emergent Biosolutions by 40.8% in the third quarter. Peregrine Capital Management LLC now owns 454,857 shares of the biopharmaceutical company’s stock valued at $18,399,000 after purchasing an additional 131,692 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Emergent Biosolutions by 16.7% in the second quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock valued at $27,820,000 after purchasing an additional 117,700 shares during the last quarter. Finally, New Amsterdam Partners LLC NY increased its holdings in shares of Emergent Biosolutions by 66.3% in the third quarter. New Amsterdam Partners LLC NY now owns 163,337 shares of the biopharmaceutical company’s stock valued at $6,607,000 after purchasing an additional 65,109 shares during the last quarter. 88.44% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Emergent Biosolutions (EBS) PT Raised to $53.00” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/16/emergent-biosolutions-ebs-pt-raised-to-53-00.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.